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Dispersion of single-walled carbon nanotubes by
a natural lung surfactant for pulmonary in vitro
and in vivo toxicity studies
Liying Wang1*, Vincent Castranova1, Anurag Mishra1,2, Bean Chen1, Robert R Mercer1, Diane Schwegler-Berry1,
Yon Rojanasakul2
Abstract
Background: Accumulating evidence indicate that the degree of dispersion of nanoparticles has a strong influence
on their biological activities. The aims of this study were to develop a simple and rapid method of nanoparticle
dispersion using a natural lung surfactant and to evaluate the effect of dispersion status of SWCNT on cytotoxicity
and fibrogenicity in vitro and in vivo.
Results: The natural lung surfactant Survanta® was used to disperse single-walled carbon nanotubes (SWCNT) in a
biological medium. At physiologically relevant concentrations, Survanta® produced well dispersed SWCNT without
causing a cytotoxic or fibrogenic effect. In vitro studies show that Survanta®-dispersed SWCNT (SD-SWCNT)
stimulated proliferation of lung epithelial cells at low doses (0.04-0.12 μg/ml or 0.02-0.06 μg/cm2 exposed surface
area) but had a suppressive effect at high doses. Non-dispersed SWCNT (ND-SWCNT) did not exhibit these effects,
suggesting the importance of dispersion status of SWCNT on bioactivities. Studies using cultured human lung
fibroblasts show that SD-SWCNT stimulated collagen production of the cells. This result is supported by a similar
observation using Acetone/sonication dispersed SWCNT (AD-SWCNT), suggesting that Survanta® did not mask the
bioactivity of SWCNT. Likewise, in vivo studies show that both SD-SWCNT and AD-SWCNT induced lung fibrosis in
mice, whereas the dispersing agent Survanta® alone or Survanta®-dispersed control ultrafine carbon black had no
effect.
Conclusions: The results indicate that Survanta® was effective in dispersing SWCNT in biological media without
causing cytotoxic effects at the test concentrations used in this study. SD-SWCNT stimulated collagen production
of lung fibroblasts in vitro and induced lung fibrosis in vivo. Similar results were observed with AD-SWCNT,
supporting the conclusion that Survanta® did not mask the bioactivities of SWCNT and thus can be used as an
effective dispersing agent. Since excessive collagen production is a hallmark of lung fibrosis, the results of this
study suggest that the in vitro model using lung fibroblasts may be an effective and rapid screening tool for
prediction of the fibrogenic potential of SWCNT in vivo.
Background
Advances in nanotechnology have made possible the
fabrication of materials at the nanoscale level. Carbon
nanotubes (CNT) are a major class of nanomaterials
possessing unique mechanical, electrical, and thermal
properties. As the use of CNT has become more wide-
spread, there has been a great concern about their
potential adverse effects on human health and the envir-
onment. Nanoparticles can come in contact with the
human body through inhalation as well as ingestion and
dermal deposition. Pulmonary exposure could occur due
to aerosolization of nanomaterials including agglomer-
ates of different size and shape. Individual CNT have a
very high aspect ratio and can agglomerate into struc-
tures which are micrometers in diameter in the dry
state or upon suspension in polar and non-polar sol-
vents [1-4]. Animal exposure studies have shown that a
major pathologic effect of CNT exposure is pulmonary
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fibrosis, and that this effect is dependent on the physio-
chemical properties of CNT [5-7]. The dispersion status
of single-walled carbon nanotubes (SWCNT) has been
shown to influence deposition pattern as well as biologi-
cal effect [5,6]. Large agglomerates deposit in the proxi-
mal alveoli and induce granulomas. In contrast, more
dispersed structures can deposit in the distal alveoli,
rapidly migrate into the alveolar walls, and induce inter-
stitial fibrosis.
To aid the investigations of pulmonary responses to
nanoparticle exposure, several in vitro and in vivo mod-
els have been developed. These studies often rely on the
use of nanoparticle preparations suspended in physiolo-
gical solutions. Since nanoparticles in solution tend to
form coarse agglomerates in physiological media, devel-
opment of methods to disperse nanoparticles is impor-
tant in assessing their biological activities. Over the
years, a variety of methods have been described to dis-
perse nanoparticles, including the use of cell culture
reagents [8,9], dimethyl sulfoxide [10], acetone [5],
pluronic surfactant [11], Tween 80 [12], and pulmonary
lavage fluids [13]. Some of these methods are laborious,
time consuming, potentially toxic, and may not mimic
physiological condition. Therefore, the aim of this study
was to develop a simple, rapid, and safe method of
nanoparticle dispersion using the natural lung surfactant
Survanta® for in vitro and in vivo studies. Survanta® is a
surfactant replacement used by health care professionals
for prevention and treatment of respiratory distress syn-
drome in premature infants. It is a sterile product con-
sisting of phospholipids and surfactant-associated
proteins SP-B and SP-C. Its commercial availability, bio-
compatibility and safety make this preparation an attrac-
tive dispersing agent for biological studies of
nanoparticles. In the present study, we evaluated the
ability of Survanta® to disperse SWCNT and investigated
the bioactivity of dispersed SWCNT in vitro and in vivo.
We also compared the effect of Survanta®-dispersed
SWCNT to SWCNT dispersions prepared by previously
published acetone/sonication and aerosolization meth-
ods [5,7,14].
Results
Nanoparticle dispersion by Survanta®
Visual inspection and corresponding micrographs of the
non-dispersed SWCNT (ND-SWCNT) and Survanta®-
dispersed SWCNT (SD-SWCNT) are shown in Figure 1.
The concentration of 150 μg/ml of Survanta® used in
this preparation is based on the content of lung surfac-
tants found in rodent lung lavage fluids [13]. Micro-
meter SWCNT agglomerates were noted in
ND-SWCNT suspension (Figure 1A). In contrast, Sur-
vanta® dispersed SWCNT into smaller size structures as
shown by visual inspection (Figure 1B, left panel) or by
regular light and hyperspectral microscopy (Figure 1B,
middle and right panels). Field emission scanning elec-
tron micrographs and count-mode particle size analysis
of ND-SWCNT and SD-SWCNT suspended structures
are shown in Figure 1 C and 1D comparing to aeroso-
lized SWCNT (Figure 1E) and Table 1, respectively. SD-
SWCNT showed suspended structures of a smaller size,
exhibiting count median width (CMW) and count med-
ian length (CML) of 0.3 μm × 1 μm, compared to ND-
SWCNT with 8 μm (CMW) × 22 μm (CML), respec-
tively (Figure 2). These results indicate that Survanta®
substantially improved the dispersion of SWCNT to
such a degree that is comparable with the structure
sizes reported for aerosolization of dry SWCNT [14].
Table 1 gives the average diameter and length of
SD-SWCNT vs. ND-SWCNT. The mean width of
SD-SWCNT was 380 nm. About two-thirds of the SD-
SWCNT were dispersed into structures with diameters
less than the average diameter of 380 nm, and more
than 8% of the dispersed particles were less than 100
nm in diameter (Table 2). In contrast, no particles with
less than 380 nm in diameter were observed in ND-
SWCNT preparations (Table 2). These results indicate
that Survanta® substantially improves the dispersion of
SWCNT at the concentration used.
Effect of Survanta® on cytotoxicity
To be useful as a dispersion agent for nanoparticles,
Survanta® should exhibit no cytotoxic effect and should
not mask the bioactivity of nanoparticles. We first tested
the cytotoxic effect of Survanta® alone in the absence of
SWCNT on lung epithelial cells by lactate dehydrogen-
ase (LDH) assay and by direct cell count. The results
show that at the concentrations tested (0.036-36 μg/ml),
Survanta® had no significant effects on the LDH release
and cell number as compared to non-treated control
(Figure 3 A and 3B), suggesting its biocompatibility at
the test concentrations.
Effects of Survanta®-dispersed SWCNT on cell growth and
toxicity
We next evaluated the effects of SWCNT, dispersed or
non-dispersed by Survanta®, on cell toxicity and prolif-
eration. Figure 4A shows that Survanta®-dispersed
SWCNT exhibited a growth stimulating effect at low
doses (0.02 and 0.06 μg/cm2 or 0.04 and 0.12 μg/ml)
and suppressing effect at the highest dose tested (0.6
μg/cm2 or 1.2 μg/ml), whereas non-dispersed SWCNT
had no effect on cell proliferation as compared to non-
treated or Survanta® only treated control. These results
suggest the importance of dispersion status of SWCNT
on their bioactivity, which is supported by the observa-
tion that SWCNT dispersed by acetone/sonication (AD-
SWCNT) also induced cell proliferation at the lowest
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Figure 1 Comparison of Survanta®-dispersed and non-dispersed SWCNT. (A) The non-dispersed SWCNT suspension (0.1 mg/ml in PBS)
shows visible clumping of the SWCNT (left panel) with corresponding light microscopy (middle panel, 100x) and hyperspectral imaging of an
individual clump (right panel, 400x). (B) The Survanta®-dispersed SWCNT suspension at the same concentration shows much improved dispersion
with no visible large clumps (left panel). Corresponding light microscopy (middle panel) and hyperspectral imaging (right panel) show a uniform
dispersion of the particles. (C-E) Field emission scanning electron microscopy of non-dispersed, Survanta®-dispersed, and aerosolized SWCNT at
low magnification (400x, left panel) and high magnification (30,000x, right panel). Aerosolization of SWCNT was performed according to the
method previously described by our group [14].
Wang et al. Particle and Fibre Toxicology 2010, 7:31
http://www.particleandfibretoxicology.com/content/7/1/31
Page 3 of 10
dose tested (Figure 4A). These data suggest that Sur-
vanta® did not mask the bioproliferative activity of
SWCNT. LDH studies show that SD-SWCNT and other
test agents were non-toxic at all concentrations tested
(Figure 4B). These results indicate that non-cytotoxic
doses of dispersed SWCNT can alter the growth pattern
of human lung epithelial cells. To our knowledge, this is
the first demonstration of the proliferative effect of low-
dose SWCNT on lung epithelial cells.
Effect of dispersed SWCNT on collagen production by
lung fibroblasts
Fibrosis is a fibroproliferative disorder characterized by
overproduction and accumulation of extracellular
Table 1 Size of non-dispersed and Survanta®-dispersed
particles
Width* (μm) Length* (μm)
SD-SWCNT 0.38 ± 0.02 1.42 ± 0.08
ND-SWCNT 12.35 ± 0.76 27.72 ± 1.86
SD-UFCB 0.70 ± 0.04 0.93 ± 0.05
ND-UFCB 5.07 ± 0.18 6.54 ± 0.2
* mean ± SD, n = 300.
Figure 2 Effect of Survanta® on SWCNT particle size and
distribution. SWCNT were dispersed in PBS in the presence or
absence of Survanta® as described in Figure 1. (A) Width distribution
of non-dispersed and Survanta®-dispersed SWCNT. (B) Length
distribution of non-dispersed and Survanta®-dispersed SWCNT. CMW
= count median width; CML = count median length; GSD =
geometric standard deviation. The size and distribution values were
determined from triplicate experiments with each experiment
measuring a minimum of 300 particles.
Table 2 Percentage of well dispersed particles in
suspension
% with width of <0.38 μm* % with width of <0.1 μm
SD-SWCNT 65.6% 8.6%
ND-SWCNT 0% 0%
% with width of <0.70 μm# % with width of <0.1 μm
SD-UFCB 73.0% 1.1%
ND-UFCB 0% 0%
* average width of SD-SWCNT; # average width of SD-UFCB.
Figure 3 Effect of Survanta® on cell toxicity and cell number.
Subconfluent (80%) cultures of human lung epithelial BEAS-2B cells
were exposed to various concentrations of Survanta® and, at one
and two days after the treatment, cells were analyzed for
cytotoxicity and cell number by LDH assay (A) and cell counting (B).
Plots are mean ± S.D. (n = 4). No significant changes over non-
treated controls were observed in all measurements at p < 0.05.
Wang et al. Particle and Fibre Toxicology 2010, 7:31
http://www.particleandfibretoxicology.com/content/7/1/31
Page 4 of 10
matrix, notably collagens [5,14]. We tested whether SD-
SWCNT can stimulate collagen production by lung
fibroblasts in culture. AD-SWCNT which have been
shown to induce interstitial lung fibrosis [5] were used
as a positive control. Ultrafine carbon black (UFCB) dis-
persed in Survanta® was used as a negative particle con-
trol. The results show that as compared to non-
treated control, Survanta® alone or SD-UFCB had no
significant effect on cellular collagen content, as deter-
mined by Sircol® assay which detects total collagen con-
tent (Figure 5A). In contrast, SD-SWCNT and AD-
SWCNT caused a substantial increase in cellular col-
lagen content at 0.02 μg/cm2 (0.04 μg/ml). Western blot
analysis of collagen I, which is the most abundant col-
lagen in the lung [15], shows a similar collagen-inducing
effect of SD-SWCNT and AD-SWCNT, whereas Sur-
vanta® alone and SD-UFCB had a minimal effect (Figure
5B). These results indicate that SD-SWCNT was able to
stimulate collagen production in lung fibroblasts and
that Survanta® used for the SWCNT dispersion had no
interfering or masking effect on the collagen-inducing
activity of SWCNT, i.e., as compared to AD-SWCNT.
Effect of dispersed SWCNT on lung fibrosis in mice
To evaluate the in vivo fibrogenic effect of SWCNT, mice
were treated with 10 μg/mouse, (~0.02 μg/cm2 of alveolar
epithelial surface area in the mouse lung) SD-SWCNT or
control treatments, and analyzed for lung collagen content
Figure 4 Effect of SWCNT on cell proliferation and cell viability.
Subconfluent (80%) cultures of lung epithelial BEAS-2B cells were
either left untreated or treated with the indicated concentrations of
non-dispersed (ND-), Survanta®-dispersed (SD-), or acetone/
sonication-dispersed (AD-) SWCNT, or Survanta® alone, or no
treatment (No Tx) for 24 h. (A) Cell proliferation was determined by
hemocytometry. (B) Cell toxicity was determined by LDH assay. Plots
are mean ± S.D. (n = 4). *p < 0.05 versus non-treated control.
Figure 5 Effect of SWCNT on fibroblast collagen production.
Subconfluent cultures of human lung fibroblast CRL-1490 cells were
either left untreated (No Tx) or treated with Survanta® alone,
Survanta®-dispersed SWCNT (SD-SWCNT), Survanta®-dispersed
ultrafine carbon black (SD-UFCB), or acetone/sonication-dispersed
SWCNT (AD-SWCNT) at a particle concentration of 0.02 μg/cm2 or
0.04 μg/ml. At 2 days after the treatment, cells were washed, lysed,
and analyzed for total collagen content by the Sircol® assay (A) or
collagen I expression by Western blotting (B), as described in the
Methods section. Equal amounts of total protein per sample were
used in all measurements. b-actin was used as a loading control for
Western blotting. The blot signals were quantified by densitometry
and mean data from independent experiments (one of which is
shown here) were normalized to the result obtained in cells without
treatment. Plots are mean ± S.D. (n = 4). *p < 0.05 versus non-
treated control.
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at two weeks post-treatment. Figure 6A shows that both
SD-SWCNT and AD-SWCNT were able to increase lung
collagen content as determined by Sircol® assay, whereas
SD-UFCB or Survanta® only treatment had no significant
effect as compared to non-treated control (No Tx). Similar
results were observed with collagen I content as
determined by Western blot assay (Figure 6B), supporting
the fibrogenic effect of SWCNT. These results are consis-
tent with the in vitro data and indicate the fibrogenic effect
of SWCNT and lack of this effect by Survanta® alone. The
observed similarity of the fibrogenic effect of SD-SWCNT
and AD-SWCNT indicates that Survanta® did not mask
the bioactivity of SWCNT.
Discussion
The major goal of this study was to evaluate the suit-
ability of utilizing Survanta® as a dispersing agent for
SWCNT to aid study of their bioactivity. The rationale
behind its use include its simplicity and rapidity of
nanoparticle dispersion (i.e., it is a single step process),
biocompatibility (i.e., it has been approved for human
clinical use), and commercial availability particularly as
a sterile preparation which greatly facilitates in vivo and
in vitro studies that require sterile conditions. In addi-
tion, one would argue that inhaled SWCNT would initi-
ally interact with alveolar lining fluid, which is modeled
by Survanta® suspension. However, the effectiveness of
this preparation in dispersing nanoparticles and its pos-
sible interfering effect on the bioactivities of SWCNT
are not known, and, therefore, are investigated in the
present study. The data presented demonstrate that Sur-
vanta® when used at the indicated concentrations is
effective in dispersing SWCNT, yielding nanoparticles
with dimensions similar to those observed after aerosoli-
zation of dry SWCNT or acetone/sonication dispersion
of SWCNT [5,14]. Non-dispersed SWCNT form large
agglomerates in phosphate-buffered saline (PBS) with an
average width of 12.35 μm and an average length of
27.72 μm. In contrast, Survanta®-dispersed SWCNT
form much smaller structures with an average width of
0.38 μm and an average length of 1.42 μm. The majority
of the dispersed SWCNT is in the form of small bundles
with no or minimum detectable individual nanotubes.
The reported average diameters of aerosolized dry
SWCNT and acetone/sonication-dispersed SWCNT are
0.24 μm and 0.6 μm, respectively [5,14]. These results
are in good agreement with previous reports showing
count median aerodynamic diameter of dry CNT gener-
ated aerosols for inhalation studies [14,16], structure
size distribution found in the workplace [17], and CNT
structures produced by surfactant dispersion [18]. The
data indicate that aerosolized dry SWCNT and surfac-
tant-dispersed SWCNT form much smaller aggregates
than SWCNT suspended in PBS. Previous animal stu-
dies also showed that well-dispersed SWCNT after pul-
monary administration exhibited similar deposited
structures and dimensions (e.g., submicron-sized aggre-
gates) as those observed in this study [5].
Ideally, in vivo pulmonary exposure studies should be
performed using an inhalation method, since it best
Figure 6 Effect of SWCNT on lung fibrosis in mice. Mice were
pharyngeal aspirated with Survanta® alone, Survanta®-dispersed
SWCNT (SD-SWCNT) or acetone/sonication-dispersed SWCNT (AD-
SWCNT), or Survanta®-dispersed ultrafine carbon black SD-UFCB) at
the particle concentration of 10 μg/mouse. At 2 weeks after the
treatment, mice were sacrificed and the lungs were isolated, lysed,
and analyzed for collagen content by the Sircol® assay (A) and
Western blotting (B). Equal amounts of total protein per sample
were used. b-actin was used as a loading control for Western
blotting. The blot signals were quantified by densitometry and
mean data from three independent experiments were normalized
to the result obtained in cells without treatment. Plots are mean ±
S.D. (n = 3). *p < 0.05 versus non-treated control (No Tx).
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mimics the human exposure condition. However, the
need for specialized facilities and equipment, trained
personnel, and large quantities of nanoparticles has lim-
ited the use of this technology. Pulmonary aspiration
represents an alternative method that has proven useful
in many pulmonary toxicity studies. This method is sim-
ple, economical, uses small amounts of nanoparticles,
and provides deep lung deposition as well as high corre-
lation to the administered dose [19]. Recent studies by
our group have shown that CNT administered by this
method produced pulmonary fibrosis in lab animals
similar to that observed after inhalation of CNT [5,6,14].
These studies suggest that the aspiration method is a
reasonable alternative method to inhalation for the
study of pulmonary fibrosis induced by nanoparticles.
Present SWCNT-size analysis further supports the
aspiration method using SD-SWCNT in which the aver-
age diameter is comparable with aerosolized dry
SWCNT using for inhalation study.
The use of Survanta® for nanoparticle dispersion pro-
vides an additional advantage over other methods of dis-
persion for pulmonary studies as it better mimics the
natural lung condition. This is particularly important for
in vitro studies which normally lack lung surfactants that
could have an effect on cell interaction and bioactivity of
nanoparticles. Previous studies have shown that lung sur-
factants aid in the displacement of particles from air to the
aqueous phase and towards the lung epithelium [19]. In
addition, when particles are present in peripheral airways
and alveoli they exist in a completely immersed, wetted
state below the surfactant film [20]. These studies suggest
that experiments using lung surfactants may be more phy-
siologically relevant than non-surfactant systems.
A key concern about the use of Survanta® is its possi-
ble adverse effects on cells and tissues or masking effect
on the exposed particles [21,22]. Our results show that
Survanta®, when used at the indicated concentrations,
had no significant cytotoxic effect on lung cells in vitro
and did not induce collagen production or mask the
fibrogenic effect of SWCNT either in vitro or in vivo.
The results of this study also indicate that dispersion
status of SWCNT is a key determinant of its biological
activities to induce cell proliferation and enhance col-
lagen production.
Another key finding of this study is the correlation
between in vitro and in vivo fibrogenic responses to
SWCNT and control particles under different dispersion
conditions. This finding suggests the potential utility of
in vitro lung fibroblasts as a predictive model for in vivo
fibrogenicity testing of CNT and other nanomaterials.
Fibrogenicity testing of nanomaterials is usually per-
formed using animals. However, this method of testing is
time-consuming, laborious, and costly. This combined
with the rapid growth in nanotechnology, which
produces an uncountable number and variety of nanoma-
terials, makes it impractical to test all of these materials
using animals. The in vitro model described here repre-
sents an alternative method that could serve as a rapid
screening tool for fibrogenicity testing of a large number
of nanomaterials. This model can also be used to conduct
detailed mechanistic studies of the fibrogenic effect of
nanoparticles, which may not be achievable in vivo.
Conclusions
The present study describes a novel method of CNT dis-
persion using the natural lung surfactant Survanta®. Sur-
vanta® was shown to be effective in dispersing SWCNT
and caused no cytotoxic or fibrogenic effect to the test
lung cells under the experimental conditions. SD-SWCNT
and AD-SWCNT similarly stimulated collagen production
of lung fibroblasts in vitro and both induced lung fibrosis
in vivo, indicating the fibrogenicity of SWCNT and non-
masking effect of Survanta®. The reported in vitro cell
model system could potentially be used to aid the fibro-
genicity testing of CNT of various size and functionaliza-
tion as well as mechanistic studies of other nanoparticles.
Methods
Particles
SWCNT (CNI, Houston, TX) were produced by the
high pressure CO disproportionation (HiPco) technique,
employing CO in a continuous-flow gas phase as the
carbon feedstock and Fe(CO)5 as the iron-containing
catalyst precursor. These SWCNT were then purified by
acid treatment to remove metal contaminates for use in
this study. Elemental analysis of the supplied SWCNT
by nitric acid dissolution and inductively coupled
plasma-atomic emission spectrometry (ICP-AES,
NMAM #7300) showed that the SWCNT were 99% ele-
mental carbon and 0.23% iron. The specific surface area
was measured at -196°C by the nitrogen absorption-
desorption technique (Brunauer Emmet Teller method,
BET) using a SA3100 Surface Area and Pore Size Analy-
zer (Beckman Coulter, Fullerton, CA). The diameter and
length distribution of poorly and well-dispersed prepara-
tions of SWCNT (without or with Survanta®) were mea-
sured by field emission scanning electron microscopy.
The surface area of dry SWCNT was 400-1,000 m2/g,
and the length and width of individual (dry) SWCNT
were 0.1-1 μm and 0.8-1.2 nm, respectively. Characteri-
zation studies were performed at NIOSH research facil-
ities as previously described [23]. The same lot of
SWCNT was used for all experiments.
Particle dispersion
SWCNT were dispersed by using Survanta® (Abbott
Laboratories, Columbus, OH) or by the acetone-sonica-
tion method as described previously [5]). Survanta®-
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dispersed SWCNT (SD-SWCNT) were prepared by dis-
persing SWCNT (0.1 mg/ml) in PBS containing Sur-
vanta® (150 μg/ml) with light sonication (Sonic Vibra
Cell Sonicator, Sonic & Material Inc, Newtown, CT,
USA) at a power of 130 W, frequency of 20 kHz, and
amplitude settings of 60% for 5-10 seconds. Non-
dispersed SWCNT (ND-SWCNT) were prepared simi-
larly but in the absence of Survanta®. Acetone/sonication
dispersed SWCNT (AD-SWCNT) were prepared accord-
ing to the method previously described [5]. Briefly,
SWCNT were treated with acetone and placed in an
ultrasonic bath for 24 h. The dispersed CNT were then
filtered from the solution using a 20-μm nylon mesh
screen followed by a 0.2-μm polytetrafluoroethylene fil-
ter. After filter collection, the dispersed CNT were
washed thoroughly with distilled water and suspended in
PBS with 2-3 minute sonication (Sonic Vibra Cell Sonica-
tor, Sonic & Material Inc, Newtown, CT, USA).
Particle imaging and size measurements
Images of SWCNT suspensions were obtained by field
emission scanning electron microscopy and nanoscale
hyperspectral microscopy. To assess the size distribution
of SWCNT samples, a sample of each was taken and fil-
tered through a polycarbonate filter (VCTP02500 iso-
pore membrane; Millipore, Billerica, MA) to collect the
particles. After washing with water and drying, the filter
was cut into equal sections, mounted onto aluminum
stubs with double-stick carbon tape, and sputter coated
with gold/palladium. The deposited particles were
viewed under a field emission scanning electron micro-
scope (model S-4800; Hitachi, Tokyo, Japan) at 400 and
30,000 magnifications. The average length and width of
the particles in each sample were determined by analysis
of a minimum of 300 particles. The size and distribution
values were determined from triplicate experiments.
Representative micrographs of the SWCNT samples
were taken using conventional and hyperspectral micro-
scopy. The latter system (CytoViva, Auburn, AL) is
capable of identifying specific material at a sub
100-nanometer resolution based on the material’s
unique spectral signature. Hyperspectral images of
SWCNT were captured with the CytoViva spectrophot-
ometer and an integrated CCD camera mounted on an
Olympus BX-51 microscope at 400x.
Cell growth and cytotoxicity
Human lung epithelial BEAS-2B cells (American Type
Culture Collection, Manassas, VA) were incubated in a
24-well plate at the density of 2 × 104 cells/well in Dul-
becco’s modified eagle medium containing 5% fetal
bovine serum. The cells were treated with various con-
centrations of Survanta®, ND-SWCNT, SD-SWCNT, or
AD-SWCNT at 37°C. At the indicated times after the
treatment, cell supernatants were collected and analyzed
for lactate dehydrogenase (LDH) as an indicator of cell
toxicity. LDH activity was determined by LDH-catalyzed
oxidation of pyruvate coupled with the reduction of
NAD at 340 nm using a commercial assay kit and a
Cobas Mira Plus transfer analyzer (Roche Diagnostics
System, Montclair, NJ). Cell growth was determined by
direct cell counting of the control and treated cells. The
cells were trypsinized, suspended in 100 μl culture med-
ium, and 10 μl samples of the suspension were mixed
with trypan blue for cell number counting and determi-
nation of cell viability using a hemocytometer.
Collagen assays
Collagen content was determined by Western blotting
and the Sircol® assay (Biocolor Ltd., Belfast, UK).
Human lung fibroblast CRL-1490 cells (ATCC, Mana-
ssas, VA) or mice were treated with Survanta®, SWCNT,
or control particles as described below. Treated cells or
mouse lung tissues were lysed and cell/tissue lysates
were analyzed for protein content using a bicinchoninic
acid protein assay kit (Pierce Biotechnology, Rockford,
IL). For Western blot analysis, equal amounts of protein
per sample (25 μg) were resolved by 10% sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a nitrocellulose membrane.
The membrane was blocked with T-PBS (0.3% Tween-
20 in PBS) containing 3% dry milk and incubated with
primary antibodies specific for collagen type I and
b-actin (Fitzgerald, Concord, MA) at 4°C overnight.
After three washes with T-PBS, the membrane was
incubated with peroxidase-conjugated secondary anti-
body for 1 h and then washed with 0.05% Tween-20 in
PBS. The immune complexes were detected by chemilu-
minescence (Supersignal® West Pico, Pierce, Rockford,
IL) and quantified using analyst/PC densitometry soft-
ware (Bio-Rad Laboratories, Hercules, CA).
For analysis of collagen content by the Sircol® assay,
cell/tissue lysates (50 μl) were incubated with Sirius red
reagent (50 μl) for 30 min, after which the collagen-dye
complex was precipitated by centrifugation at 16,000 g
for 5 min. The precipitates were washed with ethanol
and dissolved in 0.5 M NaOH. The samples were then
introduced into a microplate reader and absorbance
determined at 540 nm.
Animal exposure
Pathogen-free male C57BL/6J mice (Jackson Labora-
tories, Bar Harbor, ME) weighing 25-30 grams were
used. The animals were individually housed in an
Association for Assessment and Accreditation of
Laboratory Animal Care-accredited facility and allowed
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to acclimate at least 1 week prior to use. All experi-
mental procedures were conducted in accordance with
a protocol approved by the NIOSH Institutional Ani-
mal Care and Use Committee. The animals were trea-
ted with the test materials by pharyngeal aspiration as
described previously [24]. Briefly, animals were
anesthetized by an intraperitoneal injection of keta-
mine and xylazine (45 and 8 mg/kg) and placed on a
board in the supine position. The animal’s tongue was
extended with padded forceps. A suspension of the
test material (10 μg/100 ml per mouse) was placed on
the back of the tongue. A slight pull of the tongue
results in a reflex gasp and aspiration of the droplet.
The tongue was held, and the animal was monitored
for a few breaths after aspiration. All mice survived the
pharyngeal aspiration procedure. At given post-expo-
sure times, mice were sacrificed and lung tissues were
isolated, homogenized, lysed and analyzed for collagen
content by Western blot and Sircol® assays.
Statistics
Data were analyzed by ANOVA (STATGRAF). Bartlett’s
test was used to test for homogeneity of variances
between groups. Statistical differences were determined
by one-way ANOVA, with significance set at P < 0.05.
When significant F-values were obtained, individual
means were compared with control using a two-sided
Dunnett’s test. P < 0.05 was considered to be significant.
Data are given as means ± SD. The size distributions of
SWCNT particles in different media were determined
using the procedures described in Hinds [25].
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